TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05875935

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ECoG : electrocorticography
Description: The skull and the dura are opened under general anesthesia and the two grids of 64 cortical electrodes will be applied to the cortex, one facing the glial lesion, and the other at a distance from the glial lesion in the so-called area. Healthy (non-tumor), before the patient wakes up. They consist of 8 recording slides each comprising 8 electrodes of 2 mm in diameter each spaced 0.5 mm (DispoMed®, USA).
Study: NCT06119178

Intervention type: DEVICE
Intervention: EX-PRESS P-50 filtration device
Description: FDA-approved, stainless steel device with a 50-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed

Intervention type: DEVICE
Intervention: EX-PRESS P-200 filtration device
Description: FDA-approved, stainless steel device with a 200-micron internal lumen size indicated for the reduction of intraocular pressure in glaucoma patients where medical and conventional surgical treatments have failed
Study: NCT06580119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Somatic Psychoeducational Intervention
Description: Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Somatic Psychoeducational Intervention
Description: Participants will work on increasing bodily awareness by learning psychoeducation, movement techniques, and relaxation.
Study: NCT06511856

Intervention type: DEVICE
Intervention: ARROW
Description: Patients included in the study are patients operated with one or more shoulder medical device fabricated by FH ORTHO. Medical devices of interest are CE marked and include ARROW and ARROW prosthesis, Telegraph Evolution humeral nail and STRAPFLEX strapping system.
Study: NCT06643247

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Electroacupuncture Treatment: Needling acupoints include the Jiaji points corresponding to the spinal nerve segment of the affected area, Ashi acupoints along the affected zone, and bilateral Hegu and Waiguan points. Electroacupuncture will be performed once daily for 30 minutes per session, with a total of 7 consecutive sessions. The Jiaji and Ashi acupoints will be connected to an electroacupuncture device, set to disperse-dense wave stimulation at a frequency of 2/100 Hz, with current intensity adjusted to the patient's tolerance level.
Study: NCT05117125

Intervention type: DIAGNOSTIC_TEST
Intervention: Heparin-binding protein
Description: Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
Study: NCT04860700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anlotinib hydrochloride
Description: Patients receive anlotinib hydrochloride 12mg orally once daily on days 1-14. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Study: NCT05660369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARv3-TEAM-E T cells
Description: Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARv3-TEAM-E T cells
Description: Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARv3-TEAM-E T cells
Description: Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CARv3-TEAM-E T cells
Description: Autologous T lymphocyte population that contains cells transduced ex-vivo with a CARv3-TEAM-E lentiviral vector encoding a chimeric antigen receptor (CAR). Administered via Ommaya reservoir.
Study: NCT06200038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Reverse Natural Apophysial Glide Technique (RNAGS)
Description: Mulligan mobilization techniques was applied to the upper thoracic segments with the RNAGS technique. The application was performed with one hand (thumb in extension, other fingers flexed) that was used to perform the pushing maneuver on the transverse processes, while the other arm was used to gently grasp the head of the patient and recline the neck against the body for stabilization.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Conventional physical therapy and sham manual therapy
Description: A sham Mulligan RNAGS technique with low pressure compression was applied to thoracic region.~Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional physical therapy
Description: Conventional TENS was applied to the neck area with 2 channels and 4 electrodes for 20 min (current passage time: 50-100 microseconds, frequency: 0-120 Hz). Ultrasonography was performed for 8 minutes with an intensity of 1.5 w/cm2 and a frequency of 1 MHz. Stretching exercises were applied to the upper part of the trapezius and levator scapula muscles for 15-30 seconds for 10 repetitions by a physiotherapist
Study: NCT05692843

Intervention type: DRUG
Group type: OTHER
Intervention: Cyclosporin A
Description: Once the patient is included in the clinical trial their therapeutic management will be carried out according to usual clinical practice, but additional procedures will be performed:~1. The frequency of follow-up visits will be increased in order to collect data related to clinical efficacy, safety and quality of life;~2. Biological samples will be obtained (blood and urine) for biochemical, kinetic, pharmacogenetic and immunological biomarker analysis to identify variables associated to CsA treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Follow-up of Cyclospoin treatment already started
Description: If the patient is receiving cyclosporine therapy, a blood sample for pharmacogenetic analysis will be obtained at screening; also, at discretion of the treating physician, biological samples will be obtained (blood and urine) in this visit and in the follow-up visits to assess biochemical and kinetic variables. Clinical data (scales) will be collected from clinical records from treatment start until study inclusion and prospectively after study inclusion.~If the patient received cyclosporine previously but is no longer under CsA therapy, a blood sample will be extracted at screening for pharmacogenetic analysis. Clinical data (scales) will be collected from clinical records.
Study: NCT06085196

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindful walking activity
Description: Participate in 24 sessions of outdoor mindful walking on a local walking trail over three months

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful walking activity
Description: Participate in 24 sessions of outdoor mindful walking on a local walking trail over three months
Study: NCT05095155

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample

Intervention type: GENETIC
Intervention: SNP analysis of the DNA
Description: SNP analysis of the DNA obtained from peripheral blood sample
Study: NCT05140174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radical Healing and Internalized Stigma (RHIS) Training
Description: 8-hour RHIS training includes, readings that discuss radical healing and internalized stigma, access to didactic information regarding radical healing and internalized stigma. Therapists will role play certain scenarios that may involve minority stress experiences and discuss with the trainers different types of responses that could be therapeutic. The training will focus on the most up to date research regarding transgender mental health, minority stress, radical healing, and role-plays that focus on these processes.
Study: NCT05951699

Intervention type: DEVICE
Intervention: minimally invasive preoperative image-guided vacuum-assisted biopsy
Description: minimally invasive preoperative image-guided vacuum-assisted biopsy of the breast and needle biopsy of axillary lymph node
Study: NCT05108389

Intervention type: DIAGNOSTIC_TEST
Intervention: Viscoelastic haemostasis monitor output
Description: Observational
Study: NCT05587036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin oral tablet, 550 mg, twice daily, two-weeks
Study: NCT04658719

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Camstent Coated Catheter
Description: The patented 'M4D coating' is applied to inner and outer surfaces using a 'dip/dry' process before sterilisation, creating a safe, inert, and long-lasting finish. The coating reduces friction of the catheter surface, enhancing patient comfort on insertion and withdrawal. It also incorporates the materials which virtually preclude biofilm formation. The coating doesn't elute antibacterial agents or toxins, avoiding the build-up of dead bacteria on the device surface and retaining effectiveness throughout extended use (NB. Effectiveness is not lost because of leaching away of an active antimicrobial agent). Finally, the absence of anti-bacterial moieties means that the healthy microbial flora is not disturbed.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Uncoated Foley Catheter
Study: NCT05677867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A (PF-07081532 20 mg plus 60 mg)
Description: Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation A (PF-07081532 20 mg plus 60 mg)
Description: Formulation A: administered as a 20 mg immediate release tablet and a 60 mg immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B (PF-07081532 80 mg)
Description: Formulation B: administered as a 80 mg immediate release tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formulation B (PF-07081532 80 mg)
Description: Formulation B: administered as a 80 mg immediate release tablet
Study: NCT05826717

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple
Description: 20g fructose in \[x\] g of apple

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mashed apple
Description: 20g fructose in \[x\] g of mashed apple

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple juice
Description: 20g fructose in \[x\] ml apple juice

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fructose powder in water
Description: 20g fructose in \[x\] ml water
Study: NCT05995522

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Description: 100 µg per day for 90 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cornstarch
Description: 500 mg per day for 90 days
Study: NCT06201572

Intervention type: OTHER
Intervention: The relationship between TOI composite index and renal function in hypertensive emergency patients was compared
Description: The relationship between TOI composite index and renal function in hypertensive emergency patients was compared. The data management platform provides intelligent management of patients' out-of-hospital follow-up, and the dynamic physiological indicators and psychological assessment data of patients are mastered through the hospital port, so as to provide telemedicine guidance for patients, so as to improve the prognosis of hypertensive emergency patients.
Study: NCT06043310

Intervention type: DRUG
Intervention: Nω-nitro-L-arginine methyl ester (L-NAME)
Description: L-NAME will be infused locally through microdialysis catheters.

Intervention type: DRUG
Intervention: Nω-nitro-L-arginine methyl ester (L-NAME)
Description: L-NAME will be infused locally through microdialysis catheters.

Intervention type: DRUG
Intervention: Acetylcholine
Description: ACh will be infused locally through microdialysis catheters.
Study: NCT05117125

Intervention type: DIAGNOSTIC_TEST
Intervention: Heparin-binding protein
Description: Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.

Intervention type: DIAGNOSTIC_TEST
Intervention: Heparin-binding protein
Description: Evaluation of the specificity and sensitivity of HBP as diagnostic biomarker for VAP.
Study: NCT06043310

Intervention type: DRUG
Intervention: Acetylcholine
Description: ACh will be infused locally through microdialysis catheters.

Intervention type: DRUG
Intervention: Sodium Nitroprusside
Description: SNP will be infused locally through microdialysis catheters.

Intervention type: DRUG
Intervention: Sodium Nitroprusside
Description: SNP will be infused locally through microdialysis catheters.
Study: NCT06351215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methadone group
Description: 5mg PO methadone for participants \&lt;50kg or 10mg PO methadone for participants \&gt;50kg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: sugar pill that is identical look-alike to study drug
Study: NCT05463679

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzastaurin
Description: 500 mg QD orally in the form of four 125 mg tablets with background standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match enzastaurin 500 mg QD orally in the form of four 125 mg tablets with background standard of care
Study: NCT04770597

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aranet4 Home CO2 monitor
Description: The sensor is placed in the room at a height between 1 and 2 meters and not near the window or door.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Aranet4 Home CO2 monitor
Description: The sensor is placed in the room at a height between 1 and 2 meters and not near the window or door.
Study: NCT06020859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: undergo NaviEC-2000Pro Gastro Scan mode
Description: Patients undergo NaviEC-2000Pro Gastro Scan mode.
Study: NCT06302790

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Molli Suit Apply
Description: Exopulse Mollii Suit is a neuromodulation application that has been extensively evaluated and is a reliable technique in patients with spasticity. Unlike many neurostimulation techniques that focus only on symptomatic muscles, Suit relieves spasticity and associated pain by stimulating the weakened antagonist of the spastic muscle. Its wearable structure is designed to manage spasticity and associated pain in both upper and lower extremities.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Molli Suit Apply
Description: Exopulse Mollii Suit is a neuromodulation application that has been extensively evaluated and is a reliable technique in patients with spasticity. Unlike many neurostimulation techniques that focus only on symptomatic muscles, Suit relieves spasticity and associated pain by stimulating the weakened antagonist of the spastic muscle. Its wearable structure is designed to manage spasticity and associated pain in both upper and lower extremities.
Study: NCT06020859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaviEC-2000Pro Routine gastric examination
Description: Patients undergo NaviEC-2000Pro Routine gastric examination mode.
Study: NCT05527470

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine,Cisplatin
Description: Induction chemotherapy: Patients receive 1000 mg/m2 gemcitabine intravenously on day 1and day 8， 80mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
Study: NCT06020859

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NaviEC-1000 Routine gastric examination
Description: Patients undergo NaviEC-1000 Routine gastric examination mode.
Study: NCT05452161

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: All patients follow only the standard care of the department, which includes a preoperative group session of 1h30, with 15 to 30 participants, 6 to 8 weeks before the operation The objectives of these sessions are to inform the patients in a general way about the operation, its preparation and the postoperative process in order to standardize the information received. The content includes general information from the surgeon, explanations related to the course and management of patients by the various professionals (nurse, surgeon, anesthesist, physiotherapist, ergotherapist and liaison-nurse).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group A
Description: The day of the preparatory surgical consultation (CPC), the patient has a 30 minute patient-centered education session by a physiotherapist and a 30 minute patient-centered education session by a nurse. The physiotherapist's session addresses the technical skills to be mastered postoperatively (crutching, stairs, exercises), the course of postoperative rehabilitation, the patient's role in the rehabilitation process, the questions still remaining on this subject and the patient's perspective concerning the rehabilitation (degree and sources of anxiety, expectations of follow-up and results, degree of self-efficacy). The nursing intervention addresses the postoperative pain management, the patient's role in pain management, the care pathway, the organization of the return home and the postoperative follow-up.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention group B
Description: In addition to intervention A, patients receive a interdisciplinary intervention of three 10-15 minute phone or video conferences between the patient, a physiotherapist and a nurse.~The aim of these interviews is to identify the patient's difficulties in the living environment, to detect possible postoperative complications and to provide advice on practical aspects (e.g. ability to perform activities), therapeutic aspects (e.g. exercises to be performed, medication), pain management, interpretation of symptoms and subjective needs (e.g. need for support). Advice on rehabilitation and care is individualized according to the results of the questionnaires administered on the day of the pre-surgical consultation and those administered at discharge, as well as the needs of the moment discussed with the patient. Any suspected complication is reported to the operating physician for appropriate management.
Study: NCT05743023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ayurvedic lifestyle protocol
Description: Based on each participant's current mind-body imbalance determination, a personalized 12-week intervention lifestyle protocol will be given.~Each protocol will mainly address diet and daily routine, quality of food, food combinations, and living in harmony with natural rhythm for balancing the predominant imbalance based on Ayurvedic principles. In addition, the lifestyle protocol will also include stress-reducing methods and more specifically, participants will be recommended to learn and practice the Transcendental Meditation technique.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ayurvedic lifestyle protocol
Description: Based on each participant's current mind-body imbalance determination, a personalized 12-week intervention lifestyle protocol will be given.~Each protocol will mainly address diet and daily routine, quality of food, food combinations, and living in harmony with natural rhythm for balancing the predominant imbalance based on Ayurvedic principles. In addition, the lifestyle protocol will also include stress-reducing methods and more specifically, participants will be recommended to learn and practice the Transcendental Meditation technique.
Study: NCT05342974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral dose of atorvastatin (80 mg) to swallow at the clinic in the presence of a study provider with additional 6 doses (80 mg each) of atorvastatin to administer at home once daily for the next six days. These 6 pills should be taken orally. Return to the clinic for a follow-up visit approximately 3, 8 and 10 days after enrollment visit. At these visits, trained study clinician will evaluate abortion status using ultrasound and blood draw. At 8-day visit post-enrollment, 800 mcg of misoprostol will be provided to be taken vaginally or allowed to dissolve between cheek and tongue for 30 minutes, within 24 hours of the visit. At the final clinic visit, 10 days post-enrollment, if the termination of pregnancy has failed, standard abortion care at the clinic will be offered. A final phone call to assess any side effects, need for medical care or complications will occur 30 days after enrollment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: On Study Day 8, participant will be provided will two doses of misoprostol 800 mcg for vaginal or buccal use. Participant will take a single dose of misoprostol on study day 8 (± 1 day), and be instructed to take an additional 800 mcg vaginal or buccal misoprostol if no significant bleeding consistent with passage of tissue (heavier than a menses) has occurred within 24 hours of first misoprostol dose.
Study: NCT05527470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine,Cisplatin
Description: Induction chemotherapy: Patients receive 1000 mg/m2 gemcitabine intravenously on day 1and day 8， 80mg/m2 cisplatin intravenously on day 1 to 3, three cycles were administered at intervals of 3 weeks.
Study: NCT05436808

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial Chest Wall Radiation Therapy
Description: Patients will receive radiation therapy (30 Gray in 5 fractions) to the affected chest wall, delivered on consecutive days or every other day